

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 25

In paragraph 6, the Examiner rejected claim 54 under 35 U.S.C. §112, second paragraph for reasons of record. In response, applicants have canceled claim 54. Accordingly, the rejection should be rendered moot.

In paragraphs 7-8, the Examiner rejected claim 53 under 35 U.S.C. §112, first paragraph for reasons of record. In response, Applicants have amended the claims to recite only SEQ ID. NO. 2. Accordingly, the rejection should be rendered moot.

In paragraph 9-10, the Examiner rejected claims 53 and 54 under 35 U.S.C. §102(e) as allegedly anticipated by Au-Young for reasons of record.


In the interest of expediting prosecution, Applicants have canceled claim 54 and amended claim 53 to recite the subject matter of claims 55-69 which are free of the art. Accordingly, the rejection should be rendered moot.

In paragraph 11, the Examiner objected to claims 55-69 but indicated that these claims would be allowable if rewritten in independent form including all limitations of the base claim and any intervening claims. Applicants' amended claim 53 as indicated above. Accordingly, the rejection should be rendered moot.

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 26

No fee is due in connection with this Preliminary Amendment. However, if a fee is deemed necessary, applicants authorize the Patent Office to charge the fee to the Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano  
Registration No. 34,470  
Stephanie Hsieh  
Registration No. 38,497  
Attorneys for Applicants  
Mandel & Adriano  
55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
(626) 395-7801  
Customer No: 26,941

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 27

**VERSION WITH MARKINGS TO SHOW CHANGES MADE IN THE  
SPECIFICATION AND CLAIMS**

**In The Specification :**

Please amend the specification at page 1, lines 5-15, to read as follows:

-- This application is a Divisional application of U.S. Serial No. 09/564,329, filed May 3, 2000, which is a continuation-in-part (CIP) of U.S. Serial No. 09/359,326, filed July 20, 1999, which is a CIP of U.S. Patent No. 6,261,791, issued July 17, 2001, based on U.S. Serial No. 09/318,503, filed May 25, 1999, which is a CIP of U.S. Patent No. 6,261,789, issued July 17, 2001, based on U.S. Serial No. 09/251,835, filed February 17, 1999, which is a CIP of U.S. Patent No. 6,258,939, issued July 10, 2001, based on U.S. Serial No. 09/203,939, filed December 2, 1998, which is a CIP of U.S. Patent No. 6,267,960, issued July 31, 2001, based on U.S. Serial No. 09/038,261, filed March 10, 1998[,]; claiming the priority of provisional applications, U.S. Serial No. 60/228,816, filed March 10, 1997[,] U. S. Serial No. 60/071,141, filed January 12, 1998 and; U. S. Serial No. 60/074,675, filed February 13, 1998. This application further claims the benefit of the filing dates of U.S. Serial Nos. 60/124,658, filed March 16, 1999; 60/120,536 filed February 17, 1999; and 60/113,230 filed December 21, 1998. The contents of all of the foregoing applications are incorporated by reference into the present application. --

Please replace the paragraph at page 6, lines 18-23 with the following rewritten paragraph:

-- **FIG. 3.** Alignment of amino acid sequences of human PSCA (SEQ ID NO:5), murine PSCA (SEQ ID NO:6), and human stem cell antigen-2 (hSCA-2) (SEQ ID NO:7). Shaded regions highlight conserved amino acids. Conserved cysteines are indicated by bold lettering. Four predicted N-glycosylation sites in PSCA are indicated by asterisks. The underlined amino acids at the beginning and end of the protein represent N terminal hydrophobic signal sequences and C terminal GPI-anchoring sequences, respectively. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 28

Please replace the paragraph at page 7, lines 1-12 with the following rewritten paragraphs:

-- [FIG. 7. Restricted Expression of PSCA mRNA in normal and cancerous tissues. A: RT-PCR analysis of PSCA expression in normal human tissues demonstrating high expression in prostate, placenta, and tonsils. 1ng of reverse-transcribed first strand cDNA (Clontech, Palo Alto, CA) from the indicated tissues was amplified with PSCA gene specific primers. Data shown are from 30 cycles of amplification. B: RT-PCR analysis of PSCA expression demonstrating high level in prostate cancer xenografts and normal tissue. 5ng of reverse-transcribed cDNA from the indicated tissues was amplified with PSCA gene specific primers. Amplification with  $\beta$ -actin gene specific primers demonstrate normalization of the first strand cDNA of the various samples. Data shown are from 25 cycles of amplification. AD, androgen-dependent; AI, androgen-independent; IT, intratibial xenograft; C.L., cell line. ]

FIG. 7A. Restricted Expression of PSCA mRNA in normal and cancerous tissues. RT-PCR analysis of PSCA expression in normal human tissues demonstrating high expression in prostate, placenta, and tonsils. 1ng of reverse-transcribed first strand cDNA (Clontech, Palo Alto, CA) from the indicated tissues was amplified with PSCA gene specific primers. Data shown are from 30 cycles of amplification.

FIG. 7B. Restricted Expression of PSCA mRNA in normal and cancerous tissues. RT-PCR analysis of PSCA expression demonstrating high level in prostate cancer xenografts and normal tissue. 5 ng of reverse-transcribed cDNA from the indicated tissues was amplified with PSCA gene specific primers. Amplification with  $\beta$ -actin gene specific primers demonstrate normalization of the first strand cDNA of the various samples. Data shown are from 25 cycles of amplification. AD, androgen-dependent; AI, androgen-independent; IT, intratibial xenograft; C.L., cell line. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 29

Please replace the paragraph at page 7, lines 14-15 with the following rewritten paragraphs:

-- [FIG. 8. Schematic representation of human PSCA, murine PSCA, and human Thy-1/Ly-6 gene structures. ]

FIG. 8A. Schematic representation of human Thy-1/Ly-6 gene structures.

FIG. 8B. Schematic representation of murine PSCA gene structure.

FIG. 8C. Schematic representation of human PSCA gene structure. --

Please replace the paragraph at page 7, lines 17-22 with the following rewritten paragraphs:

-- [FIG. 9. Northern blot analysis of PSCA expression. A: Total RNA from normal prostate and LAPC-4 androgen dependent (AD) and independent (AI) prostate cancer xenografts were analyzed using PSCA or PSA specific probes. Equivalent RNA loading and RNA integrity were demonstrated separately by ethidium staining for 18S and 28S RNA. B: Human multiple tissue Northern blot analysis of PSCA. The filter was obtained from Clontech (Palo Alto, CA) and contains 2ug of polyA RNA in each lane. ]

FIG. 9A. Northern blot analysis of PSCA expression. Total RNA from normal prostate and LAPC-4 androgen dependent (AD) and independent (AI) prostate cancer xenografts were analyzed using PSCA or PSA specific probes. Equivalent RNA loading and RNA integrity were demonstrated separately by ethidium staining for 18S and 28S RNA.

FIG. 9B. Northern blot analysis of PSCA expression. Human multiple tissue Northern blot analysis of PSCA. The filter was obtained from Clontech (Palo Alto, CA) and contains 2ug of polyA RNA in each lane. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 30

Please replace the paragraph at page 7, lines 24-30, and continuing through page 8, lines 1-2, with the following rewritten paragraphs:

-- [FIG. 10. Northern blot comparison of PSCA, PSMA, and PSA expression in prostate cancer xenografts and tumor cell lines. PSCA and PSMA demonstrate high level prostate cancer specific gene expression. 10  $\mu$ g of total RNA from the indicated tissues were size fractionated on an agarose/formaldehyde gel, transferred to nitrocellulose, and hybridized sequentially with  $^{32}$ P-labelled probes representing PSCA, PSMA, and PSA cDNA fragments. Shown are 4 hour and 72 hour autoradiographic exposures of the membrane and the ethidium bromide gel demonstrating equivalent loading of samples. BPH, benign prostatic hyperplasia; AD, androgen-dependent; AI, androgen-independent; IT, intratibial xenograft; C.L., cell line. ]

FIG. 10A. Northern blot analysis of PSCA expression in prostate cancer xenografts and tumor cell lines. PSCA demonstrates high level prostate cancer specific gene expression. 10  $\mu$ g of total RNA from the indicated tissues were size fractionated on an agarose/formaldehyde gel, transferred to nitrocellulose, and hybridized sequentially with  $^{32}$ P-labelled probes representing PSCA cDNA fragments. Shown are 4 hour and 72 hour autoradiographic exposures of the membrane. BPH, benign prostatic hyperplasia; AD, androgen-dependent; AI, androgen-independent; IT, intratibial xenograft; C.L., cell line.

FIG. 10B. Northern blot analysis of PSM expression in prostate cancer xenografts and tumor cell lines. PSM demonstrates high level prostate cancer specific gene expression. 10  $\mu$ g of total RNA from the indicated tissues were size fractionated on an agarose/formaldehyde gel, transferred to nitrocellulose, and hybridized sequentially with  $^{32}$ P-labelled probes representing PSM cDNA fragments. Shown are 4 hour and 72 hour autoradiographic exposures of the membrane. BPH, benign prostatic hyperplasia; AD, androgen-dependent; AI, androgen-independent; IT, intratibial xenograft; C.L., cell line.

FIG. 10C. Northern blot analysis of PSA expression in prostate cancer xenografts and tumor cell lines. 10  $\mu$ g of total RNA from the indicated tissues were size fractionated on

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 31

an agarose/formaldehyde gel, transferred to nitrocellulose, and hybridized sequentially with <sup>32</sup>P-labelled probes representing PSA cDNA fragments. Shown are 4 hour and 72 hour autoradiographic exposures of the membrane and the ethidium bromide gel demonstrating equivalent loading of samples. BPH, benign prostatic hyperplasia; AD, androgen-dependent; AI, androgen-independent; IT, intratibial xenograft; C.L., cell line.

--

Please replace the paragraph at page 8, lines 4-11 with the following rewritten paragraphs:

-- [FIG. 11. In situ hybridization with antisense riboprobe for human PSCA on normal and malignant prostate specimens. A: PSCA is expressed by a subset of basal cells within the basal cell epithelium (black arrows), but not by the terminally differentiated secretory cells lining the prostatic ducts (400X magnification). B: PSCA is expressed strongly by a high grade prostatic intraepithelial neoplasia (PIN) (black arrow) and by invasive prostate cancer glands (yellow arrows), but is not detectable in normal epithelium (green arrow) at 40X magnification. C: Strong expression of PSCA in a case of high grade carcinoma (200X magnification). ]

FIG. 11A. In situ hybridization with antisense riboprobe for human PSCA on normal prostate specimens. PSCA is expressed by a subset of basal cells within the basal cell epithelium (black arrows), but not by the terminally differentiated secretory cells lining the prostatic ducts (400X magnification).

FIG. 11B. In situ hybridization with antisense riboprobe for human PSCA on normal and malignant prostate specimens. PSCA is expressed strongly by a high grade prostatic intraepithelial neoplasia (PIN) (black arrow) and by invasive prostate cancer glands (yellow arrows), but is not detectable in normal epithelium (green arrow) at 40X magnification.

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 32

FIG. 11C. In situ hybridization with antisense riboprobe for human PSCA on malignant prostate specimens. Strong expression of PSCA in a case of high grade carcinoma (200X magnification). --

Please replace the paragraph at page 8, lines 13-22 with the following rewritten paragraphs:

-- [FIG. 12. Biochemical analysis of PSCA. **A:** PSCA was immunoprecipitated from 293T cells transiently transfected with a PSCA construct and then digested with either N-glycosidase F or O-glycosidase, as described in Materials and Methods. **B:** PSCA was immunoprecipitated from 293T transfected cells, as well as from conditioned media of these cells. Cell-associated PSCA migrates higher than secreted or shed PSCA on a 15% polyacrylamide gel. **C:** FACS analysis of mock-transfected 293T cells, PSCA-transfected 293T cells and LAPC-4 prostate cancer xenograft cells using an affinity purified polyclonal anti-PSCA antibody. Cells were not permeabilized in order to detect only surface expression. The y axis represents relative cell number and the x axis represents fluorescent staining intensity on a logarithmic scale. ]

FIG. 12A. Biochemical analysis of PSCA. PSCA was immunoprecipitated from 293T cells transiently transfected with a PSCA construct and then digested with either N-glycosidase F or O-glycosidase, as described in Materials and Methods.

FIG. 12B. Biochemical analysis of PSCA. PSCA was immunoprecipitated from 293T transfected cells, as well as from conditioned media of these cells. Cell-associated PSCA migrates higher than secreted or shed PSCA on a 15% polyacrylamide gel.

FIG 12C. Biochemical analysis of PSCA. FACS analysis of mock-transfected 293T cells, PSCA-transfected 293T cells, and LAPC-4 prostate cancer xenograft cells using an affinity purified polyclonal anti-PSCA antibody. Cells were not permeabilized in order to detect only surface expression. The y axis represents relative cell number and the x axis represents fluorescent staining intensity on a logarithmic scale. --



Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 33

Please replace the paragraph at page 9, lines 1-6 with the following rewritten paragraphs:

-- [FIG. 14. Flow Cytometric analysis of cell surface PSCA expression on prostate cancer xenograft (LAPC-9), prostate cancer cell line (LAPC-4) and normal prostate epithelial cells (PreC) using anti-PSCA monoclonal antibodies 1G8 (green) and 3E6 (red), mouse anti-PSCA polyclonal serum (blue), or control secondary antibody (black). See Example 5 for details. ]

FIG. 14A. Flow Cytometric analysis of cell surface PSCA expression on prostate cancer xenograft (LAPC-9) using anti-PSCA monoclonal antibodies 1G8 and 3E6, mouse anti-PSCA polyclonal serum, or control secondary antibody. See Example 5 for details.

FIG. 14B. Flow Cytometric analysis of cell surface PSCA expression on prostate cancer cell line (LAPC-4) using anti-PSCA monoclonal antibodies 1G8 and 3E6, mouse anti-PSCA polyclonal serum, or control secondary antibody. See Example 5 for details.

FIG 14C. Flow Cytometric analysis of cell surface PSCA expression on normal prostate epithelial cells (PreC) using anti-PSCA monoclonal antibodies 1G8 and 3E6, mouse anti-PSCA polyclonal serum, or control secondary antibody. See Example 5 for details. --

Please replace the paragraph at page 9, lines 8-10 with the following rewritten paragraphs:

-- [FIG. 15. (a) An epitope map for each of the seven disclosed antibodies. (b) Epitope mapping of anti-PSCA monoclonal antibodies conducted by Western blot analysis of GST-PSCA fusion proteins. ]

FIG. 15A. An epitope map for each of the seven disclosed antibodies.

FIG 15B. Epitope mapping of anti-PSCA monoclonal antibodies conducted by Western blot analysis of GST-PSCA fusion proteins. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 34

Please replace the paragraph at page 9, line 12 with the following rewritten paragraphs:

-- [FIG. 16. A schematic diagram showing that PSCA is a GPI-anchored protein. ]

**FIG. 16A.** Alignment of amino acid sequences of human PSCA, murine PSCA, and human stem cell antigen-2 (hSCA-2). Shaded regions highlight conserved amino acids.

**FIG. 16B** A schematic diagram showing that PSCA is a GPI-anchored protein. --

Please replace the paragraph at page 12, lines 6-12 with the following rewritten paragraph:

FIG. 37[(A)]. A photograph showing immunological reactivity of anti-[PSCA]mAbs.

Immunoprecipitation of PSCA from 293T cells transiently transfected with PSCA using mAbs 1G8, 2H9, 3C5, 3E6 and 4A10. The control was an irrelevant murine IgG mAb. [(B) Immunoblot analysis of 293T cells transiently transfected with PSCA using the five anti-PSCA mAbs. mAbs 1G8, 3C5 and 4A10 all recognize equivalent molecular forms of PSCA, whereas mAbs 2H9 and 3E6 only weakly recognize deglycosylated forms of PSCA in 293T-PSCA cells in this assay. ] --

Please replace the paragraph at page 12, lines 22-30 with the following rewritten paragraphs:

-- [Figure 39. Expression of PSCA in normal tissues. (A) Panel *a* shows staining of bladder transitional epithelium with mAb 1G8. Panel *b* shows colonic neuroendocrine cell staining with mAb 1G8. Double staining with chromogranin confirmed that the positive cells are of neuroendocrine origin (not shown). Panel *c* shows staining of collecting ducts (arrow) and tubules with mAb 3E6. Panel *d* show staining of placental trophoblasts with mAb 3E6. (B) Northern blot analysis of PSCA mRNA expression. Total RNA from normal prostate, kidney, bladder and the LAPC-9 prostate cancer xenograft was analyzed using a PSCA specific probe (top panel). The same membrane was probed with actin to control of loading differences (bottom panel). ]

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 35

**FIG. 39A.** Expression of PSCA in normal tissues. Panel *a* shows staining of bladder transitional epithelium with mAb 1G8. Panel *b* shows colonic neuroendocrine cell staining with mAb 1G8. Double staining with chromogranin confirmed that the positive cells are of neuroendocrine origin (not shown). Panel *c* shows staining of collecting ducts (arrow) and tubules with mAb 3E6. Panel *d* show staining of placental trophoblasts with mAb 3E6.

**FIG. 39B.** Expression of PSCA in normal tissues. Northern blot analysis of PSCA mRNA expression. Total RNA from normal prostate, kidney, bladder and the LAPC-9 prostate cancer xenograft was analyzed using a PSCA specific probe (top panel). The same membrane was probed with actin to control of loading differences (bottom panel).

--

Please replace the paragraph at page 13, lines 1-4 with the following rewritten paragraphs:

-- [Figure 40. Targeting of mouse PSCA gene. (A) Panel *a* is a schematic drawing showing a strategy for creating a PSCA targeting vector. (B) Panel *b* is a photograph of a southern blot analysis of genomic DNA using 3' probe showing recovery of wild-type (+/+) and heterozygous (+/-) ES cells. ]

**FIG. 40A.** Targeting of mouse PSCA gene. A schematic drawing showing a strategy for creating a PSCA targeting vector.

**FIG. 40B.** Targeting of mouse PSCA gene. A photograph of a Southern blot analysis of genomic DNA using 3' probe showing recovery of wild-type (+/+) and heterozygous (+/-) ES cells. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 36

Please replace the paragraph at page 13, lines 27-28 with the following rewritten paragraphs:

-- [Photographs of multiple tissue northern blot analysis showing tissue specific expression patterns of human and murine PSCA RNA.]

FIG. 47A. Photograph of a multiple tissue Northern blot analysis showing tissue specific expression patterns of human PSCA RNA.

FIG. 47B. Photograph of a multiple tissue Northern blot analysis showing tissue specific expression patterns of murine PSCA RNA. --

Please replace the paragraph at page 13, lines 30-31, and continuing through page 14, lines 1-6, with the following rewritten paragraphs:

-- [FIG. 48. Complete inhibition of LAPC-9 prostate tumor growth in SCID mice by treatment with anti-PSCA monoclonal antibodies. The upper panel represents mice injected with LAPC-9 s.c. and treated with a mouse IgG control, while in the lower panel mice were injected with LAPC-9 s.c. but treated with the anti-PSCA mAb cocktail. Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-A, infra. In the anti-PSCA group, an arbitrary value of 20 was given for all data points to create a line, although the actual tumor volume was 0 (Example 18-A, infra). ]

FIG. 48A. Complete inhibition of LAPC-9 prostate tumor growth in SCID mice by treatment with anti-PSCA monoclonal antibodies. Mice were injected with LAPC-9 s.c. and treated with a mouse IgG control. Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-A, infra.

FIG. 48B. Complete inhibition of LAPC-9 prostate tumor growth in SCID mice by treatment with anti-PSCA monoclonal antibodies. Mice were injected with LAPC-9 s.c. and treated with the anti-PSCA mAb cocktail. Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-A, infra. In the

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 37

anti-PSCA group, an arbitrary value of 20 was given for all data points to create a line, although the actual tumor volume was 0 (Example 18-A, infra). --

Please replace the paragraph at page 14, lines 7-19 with the following rewritten paragraphs:

-- [FIG. 49. Characteristics of anti-PSCA monoclonal antibodies utilized in the in vivo tumor challenge study described in Example 18. (A) Isotype and epitope map: The region of PSCA protein recognized by the anti-PSCA mAbs was determined by ELISA analysis using GST-fusion proteins (50ng/well) encoding the indicated amino acids of PSCA. Following incubation of wells with hybridoma supernatants, anti-mouse-HRP conjugate antibody was added and reactivity was determined by the addition of 3,3' 5,5'-Tetramethylbenzidine base (TMB) substrate. Optical densities (450nm) are the means of duplicate determinations. (B) Epitope map determined by Western analysis: 50ng of the indicated GST-PSCA fusion protein was separated by SDS-PAGE and transferred to nitrocellulose. Western analysis was carried out by incubation of blots with hybridoma supernatants followed by anti-mouse-HRP secondary Ab and visualized by enhanced chemiluminescence. ]

FIG. 49A. Characteristics of anti-PSCA monoclonal antibodies utilized in the in vivo tumor challenge study described in Example 18. Isotype and epitope map: The region of PSCA protein recognized by the anti-PSCA mAbs was determined by ELISA analysis using GST-fusion proteins (50ng/well) encoding the indicated amino acids of PSCA. Following incubation of wells with hybridoma supernatants, anti-mouse-HRP conjugate antibody was added and reactivity was determined by the addition of 3,3' 5,5'-Tetramethylbenzidine base (TMB) substrate. Optical densities (450nm) are the means of duplicate determinations.

FIG. 49B. Characteristics of anti-PSCA monoclonal antibodies utilized in the in vivo tumor challenge study described in Example 18. Epitope map determined by Western analysis: 50ng of the indicated GST-PSCA fusion protein was separated by SDS-PAGE

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 38

and transferred to nitrocellulose. Western analysis was carried out by incubation of blots with hybridoma supernatants followed by anti-mouse-HRP secondary Ab and visualized by enhanced chemiluminescence. --

Please replace the paragraph at page 14, lines 21-28 with the following rewritten paragraphs:

-- [FIG. 50. Schematic representations of PSCA Capture ELISA. (A) Standardization and control antigens: A GST-fusion protein encoding amino acids 18-98 of the PSCA protein is used for generating a standard curve for quantification of unknown samples. Also depicted are approximate epitope binding regions of the anti-PSCA monoclonal and polyclonal antibodies used in the ELISA. A secreted recombinant mammalian expressed form of PSCA is used for quality control of the ELISA assay. This protein contains an Ig leader sequence to direct secretion of the recombinant protein and MYC and 6XHIS epitope tags for affinity purification. (B) ELISA format schematic. ]

FIG. 50A. Schematic representations of PSCA Capture ELISA. Standardization and control antigens: A GST-fusion protein encoding amino acids 18-98 of the PSCA protein is used for generating a standard curve for quantification of unknown samples. Also depicted are approximate epitope binding regions of the anti-PSCA monoclonal and polyclonal antibodies used in the ELISA. A secreted recombinant mammalian expressed form of PSCA is used for quality control of the ELISA assay. This protein contains an Ig leader sequence to direct secretion of the recombinant protein and MYC and 6XHIS epitope tags for affinity purification.

FIG. 50B. Schematic representations of PSCA Capture ELISA. An ELISA format schematic. --

Applicant: Robert E. Reiter, et al.  
 U.S. Serial No.: 09/855,153  
 Filed: May 14, 2001  
 Page 39

Please replace the paragraph at page 14, lines 30-31 and continuing through page 15, lines 1-5 with the following rewritten paragraphs:

-- [FIG. 51. Quantification of recombinant secreted PSCA protein. (A) PSCA capture ELISA standard curve. (B) Quantification of PSCA protein secreted by mammalian cells. 2 day conditioned tissue culture supernatants from either 293T cells transfected with empty vector or with vector encoding recombinant secreted PSCA (secPSCA) was mixed with an equal volume of either PBS or normal human serum (Omega Scientific) and analyzed for the presence of PSCA protein. Data are the means of duplicate determinations  $\pm$  range. ND not detectable.]

FIG. 51A. Quantification of recombinant secreted PSCA protein. PSCA capture ELISA standard curve.

FIG. 51B. Quantification of PSCA protein secreted by mammalian cells. 2 day conditioned tissue culture supernatants from either 293T cells transfected with empty vector or with vector encoding recombinant secreted PSCA (secPSCA) was mixed with an equal volume of either PBS or normal human serum (Omega Scientific) and analyzed for the presence of PSCA protein. Data are the means of duplicate determinations  $\pm$  range. ND not detectable. --

Please replace the paragraph at page 15, lines 10-15 with the following rewritten paragraphs:

-- [FIG. 53. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies. The top panel represents mice injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with a mouse IgG control (n = 10), the middle panel represents mice injected with LAPC-9 s.c. and treated with anti-PSCA mAb cocktail (n = 10), the bottom panel represents mice injected with LAPC-9 s.c. and treated with bovine IgG (n = 5). Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-B.]

FIG. 53A. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies. Mice were injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with a mouse IgG control (n =

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 40

10). Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-B.

FIG. 53B. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies. Mice were injected with LAPC-9 s.c. and treated with anti-PSCA mAb cocktail (n = 10). Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-B.

FIG. 53C. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies. Mice were injected with LAPC-9 s.c. and treated with bovine IgG (n = 5). Each data point represents the ellipsoidal volume of tumors at specified time points as described in Example 18-B. --

Please replace the paragraph at page 15, lines 17-21 with the following rewritten paragraphs:

-- [FIG. 54. Inhibition of LAPC-9 tumor growth by the anti-PSCA monoclonal antibody 1G8. The upper panel represents mice injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with a mouse IgG control (n = 6), while in the lower panel mice were injected with LAPC-9 s.c. but treated with the anti-PSCA mAb 1G8 (n = 7). Each data point represents the ellipsoidal volume of tumors at specified time points. ]

FIG. 54A. Inhibition of LAPC-9 tumor growth by the anti-PSCA monoclonal antibody 1G8. Mice were injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with a mouse IgG control (n = 6). Each data point represents the ellipsoidal volume of tumors at specified time points.

FIG. 54B. Inhibition of LAPC-9 tumor growth by the anti-PSCA monoclonal antibody 1G8. Mice were injected with LAPC-9 s.c. and treated with the anti-PSCA mAb 1G8 (n = 7). Each data point represents the ellipsoidal volume of tumors at specified time points.

--



Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 41

Please replace the paragraph at page 15, lines 23-29 with the following rewritten paragraphs:

-- [FIG. 55. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies 2A2 and 2H9. The upper panel represents mice injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with either a mouse IgG control ( $n = 6$ ) or the 2A2 mAb ( $n = 7$ ). The lower panel represents mice injected with LAPC-9 s.c. and treated with the same mouse IgG control ( $n = 6$ ) or the 2H9 mAb ( $n = 7$ ). All data points represent the mean ellipsoidal volume of tumors ( $\text{mm}^3$ ) at the specified time points. Error bars represent standard error of the mean (SEM).]

FIG. 55A. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies 2A2 and 2H9. Mice were injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with either a mouse IgG control ( $n = 6$ ) or the 2A2 mAb ( $n = 7$ ). All data points represent the mean ellipsoidal volume of tumors ( $\text{mm}^3$ ) at the specified time points. Error bars represent standard error of the mean (SEM).

FIG. 55B. Inhibition of LAPC-9 tumor growth by anti-PSCA monoclonal antibodies 2A2 and 2H9. Mice were injected with LAPC-9 s.c. and treated with the same mouse IgG control ( $n = 6$ ) or the 2H9 mAb ( $n = 7$ ). All data points represent the mean ellipsoidal volume of tumors ( $\text{mm}^3$ ) at the specified time points. Error bars represent standard error of the mean (SEM). --

Please replace the paragraph at page 16, lines 1-7 with the following rewritten paragraphs:

-- [FIG. 56. Circulating PSA levels in LAPC-9 tumor-injected mice after treatment with anti-PSCA mAbs 2A2 and 2H9. The upper panel represents the mice injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with either the mouse IgG control ( $n = 6$ ) or the 2A2 mAb ( $n = 7$ ). The lower panel represents mice injected with LAPC-9 s.c. but treated with either the same mouse IgG control ( $n = 6$ ) or the 2H9 mAb ( $n = 7$ ). Each data point represents

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 42

the mean PSA level determined from the serum of mice at weekly time points. Error bars represent standard error of the mean (SEM). ]

FIG. 56A. Circulating PSA levels in LAPC-9 tumor-injected mice after treatment with anti-PSCA mAbs 2A2 and 2H9. Mice were injected with  $1 \times 10^6$  LAPC-9 s.c. and treated with either the mouse IgG control (n = 6) or the 2A2 mAb (n = 7). Each data point represents the mean PSA level determined from the serum of mice at weekly time points. Error bars represent standard error of the mean (SEM).

FIG. 56B. Circulating PSA levels in LAPC-9 tumor-injected mice after treatment with anti-PSCA mAbs 2A2 and 2H9. Mice were injected with LAPC-9 s.c. and treated with either the same mouse IgG control (n = 6) or the 2H9 mAb (n = 7). Each data point represents the mean PSA level determined from the serum of mice at weekly time points. Error bars represent standard error of the mean (SEM). --

Please replace the paragraph at page 16, lines 12-13 with the following rewritten paragraph:

-- [FIG. 58. Amino acid sequence of the heavy chain variable domain regions of PSCA monoclonal antibodies 1G8. CDRs are labeled and underlined. ]

FIG. 58. Nucleotide sequence (SEQ ID NO:10) and amino acid sequence (SEQ ID NO:11) of the heavy chain variable domain regions of PSCA monoclonal antibodies 1G8. CDRs are labeled and underlined. --

Please replace the paragraph at page 16, lines 15-16 with the following rewritten paragraph:

-- [FIG. 59. Amino acid sequence of the heavy chain variable domain regions of PSCA monoclonal antibodies 4A10. CDRs are labeled and underlined. ]

FIG. 59. Nucleotide sequence (SEQ ID NO:12) and amino acid sequence (SEQ ID NO:13) of the heavy chain variable domain regions of PSCA monoclonal antibodies 4A10. CDRs are labeled and underlined. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 43

Please replace the paragraph at page 16, lines 18-19 with the following rewritten paragraph:

-- [FIG. 60. Amino acid sequence of the heavy chain variable domain regions of PSCA monoclonal antibodies 2H9. CDRs are labeled and underlined. ]

FIG. 60. Nucleotide sequence (SEQ ID NO:14) and amino acid sequence (SEQ ID NO:15) of the heavy chain variable domain regions of PSCA monoclonal antibodies 2H9. CDRs are labeled and underlined. --

Please replace the paragraph at page 16, lines 24-25 with the following rewritten paragraphs:

-- [FIG. 62. Photographs showing PSCA protein expression in normal bladder and various bladder carcinoma tissues using immunohistochemical staining of paraffin-embedded samples with PSCA mAb 1G8. ]

FIG. 62A. Photograph showing PSCA protein expression in normal bladder tissue using immunohistochemical staining of paraffin-embedded samples with PSCA mAb 1G8.

FIG. 62B. Photograph showing PSCA protein expression in non-invasive superficial papillar tissue using immunohistochemical staining of paraffin-embedded samples with PSCA mAb 1G8.

FIG. 62C. Photograph showing PSCA protein expression in carcinoma in situ, a high grade pre-cancerous lesion, using immunohistochemical staining of paraffin-embedded samples with PSCA mAb 1G8.

FIG. 62D. Photograph showing PSCA protein expression in invasive bladder cancer tissue using immunohistochemical staining of paraffin-embedded samples with PSCA mAb 1G8. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 44

Please replace the paragraph at page 17, lines 5-9 with the following rewritten paragraphs:

-- [FIG. 65. PSCA mAbs exert growth inhibitory effect through PSCA protein. The growth inhibitory effect of PSCA mAb 1G8 on LAPC-9 and PC-3 prostate tumors is compared, showing no effect on PC-3 tumors, which do not express PSCA antigen, but significant growth inhibition in LAPC-9 tumors, which do express PSCA antigen. See Examples 18-C1, -C3 for details.]

FIG. 65A. PSCA mAbs exert growth inhibitory effect through PSCA protein. The growth inhibitory effect of PSCA mAb 1G8 on LAPC-9 prostate tumors showing significant growth inhibition in LAPC-9 tumors, which express PSCA antigen. See Examples 18-C1, -C3 for details.

FIG. 65B. PSCA mAbs exert growth inhibitory effect through PSCA protein. The growth inhibitory effect of PSCA mAb 1G8 on PC-3 prostate tumors, showing no effect on PC-3 tumors, which do not express PSCA antigen. See Examples 18-C1, -C3 for details, --

Please replace the paragraph at page 17, lines 11-16 with the following rewritten paragraphs:

-- [FIG. 66. Growth inhibition of established LAPC-9 (AD) orthotopic tumors by the anti-PSCA mAb 1G8. (A) Mice having low levels of serum PSA. Two mg of 1G8 was administered to these mice on days 10, 13, and 15, followed by one mg on days 17, 20, 22, 25, 27, 29, 34, 41, and 49 as indicated by the arrows. (B) Mice having moderate levels of serum PSA. One mg of 1G8 was administered on days 12, 13, 14, 19, 20, 22, 25, 27, 29, and 33 as indicated by the arrows.]

FIG. 66A. Growth inhibition of established LAPC-9 (AD) orthotopic tumors by the anti-PSCA mAb 1G8. Mice having low levels of serum PSA. Two mg of 1G8 was administered to these mice on days 10, 13, and 15, followed by one mg on days 17, 20, 22, 25, 27, 29, 34, 41, and 49 as indicated by the arrows.

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 45

**FIG. 66B.** Growth inhibition of established LAPC-9 (AD) orthotopic tumors by the anti-PSCA mAb 1G8. Mice having moderate levels of serum PSA. One mg of 1G8 was administered on days 12, 13, 14, 19, 20, 22, 25, 27, 29, and 33 as indicated by the arrows.

Please replace the paragraph at page 17, lines 18-22 with the following rewritten paragraphs:

-- [FIG. 67. Treatment with the anti-PSCA mAb, 1G8, increases survival of mice bearing established LAPC-9 (AD) orthotopic tumors. (A) The mice in Figure 66 A, which were treated with 1G8, exhibited an increase in survival compared to mice treated with PBS. (B) The mice in Figure 66 B, which were treated with 1G8, exhibited an increase in survival compared to mice treated with PBS. ]

**FIG. 67A.** Treatment with the anti-PSCA mAb, 1G8, increases survival of mice bearing established LAPC-9 (AD) orthotopic tumors. Mice treated with 1G8 exhibited an increase in survival compared to mice treated with PBS.

**FIG. 67B.** Treatment with the anti-PSCA mAb, 1G8, increases survival of mice bearing established LAPC-9 (AD) orthotopic tumors. Mice treated with PBS. --

Please replace the paragraph at page 17, lines 24-30 with the following rewritten paragraphs:

-- [FIG. 68. Growth inhibition of established LAPC-9 AD orthotopic tumors by the anti-PSCA mAb 3C5. (A) One mg of 3C5 was administered to tumor-bearing mice on days 6, 8, 10, 13, 15, 17, 20, 22, 24, and 29 as indicated by the arrows. The mice were bled on the days indicated on the X-axis for PSA determinations. (B) Two mg of 3C5 was administered to tumor-bearing mice on days 9, 12, and 15, followed by one mg on days 18, 20, 22, 25, 27, and 29 as indicated by the arrows. The mice were bled on the days indicated on the X-axis for PSA determinations. ]

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 46

FIG. 68A. Growth inhibition of established LAPC-9 AD orthotopic tumors by the anti-PSCA mAb 3C5. One mg of 3C5 was administered to tumor-bearing mice on days 6, 8, 10, 13, 15, 17, 20, 22, 24, and 29 as indicated by the arrows. The mice were bled on the days indicated on the X-axis for PSA determinations.

FIG. 68B. Growth inhibition of established LAPC-9 AD orthotopic tumors by the anti-PSCA mAb 3C5. Two mg of 3C5 was administered to tumor-bearing mice on days 9, 12, and 15, followed by one mg on days 18, 20, 22, 25, 27, and 29 as indicated by the arrows. The mice were bled on the days indicated on the X-axis for PSA determinations.

--

Please replace the paragraph at page 18, lines 1-7 with the following rewritten paragraphs:

-- [FIG. 69. Treatment with the anti-PSCA mAb, 3C5, increases survival of mice bearing LAPC-9 AD orthotopic tumors. (A) The mice in Figure 68 A, which were treated with 3C5, exhibited an increase in survival compared to mice treated with PBS. There were 4 mice in the PBS-treated group and 5 mice in the 3C5-treated group. (B) The mice in Figure 68 B, which were treated with 3C5, exhibited an increase in survival compared to mice treated with PBS. There were 6 mice in both the PBS-treated and 3C5-treated groups. ]

FIG. 69A. Treatment with the anti-PSCA mAb, 3C5, increases survival of mice bearing LAPC-9 AD orthotopic tumors. Mice treated with 3C5 exhibited an increase in survival compared to mice treated with PBS. There were 4 mice in the PBS-treated group and 5 mice in the 3C5-treated group.

FIG. 69B. Treatment with the anti-PSCA mAb, 3C5, increases survival of mice bearing LAPC-9 AD orthotopic tumors. Mice treated with 3C5 exhibited an increase in survival compared to mice treated with PBS. There were 6 mice in both the PBS-treated and then 3C5-treated groups. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 47

Please replace the paragraph at page 18, lines 15-19 with the following rewritten paragraphs:

-- [FIG. 71. Anti-PSCA antibody administered to tumor-bearing mice circulates and targets tumors expressing PSCA. A) Immunohistochemistry of a tumor explant from a mouse, bearing an established PSCA-expressing tumor, treated with 3C5. B) Immunohistochemistry of a tumor explant from a mouse, bearing an established PSCA-expressing tumor, treated with mouse IgG. ]

FIG. 71A. Anti-PSCA antibody administered to tumor-bearing mice circulates and targets tumors expressing PSCA. Immunohistochemistry of a tumor explant from a mouse, bearing an established PSCA-expressing tumor, treated with 3C5.

FIG. 71B. Anti-PSCA antibody administered to tumor-bearing mice circulates and targets tumors expressing PSCA. Immunohistochemistry of a tumor explant from a mouse, bearing an established PSCA-expressing tumor, treated with mouse IgG. --

Please replace the paragraph at page 20, lines 16-26 with the following rewritten paragraph:

-- One aspect of the invention provides various PSCA proteins and peptide fragments thereof. As used herein, PSCA refers to a protein that has the amino acid sequence of human PSCA (SEQ ID NO:2) as provided in FIGS. 1B and 3, the amino acid sequence of the murine PSCA homologue (SEQ ID NO:4) as provided in FIG. 3, or the amino acid sequence of other mammalian PSCA homologues, as well as allelic variants and conservative substitution mutants of these proteins that have PSCA activity. The PSCA proteins of the invention include the specifically identified and characterized variants herein described, as well as allelic variants, conservative substitution variants and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined below. For the sake of convenience, all PSCA proteins will be collectively referred to as the PSCA proteins, the proteins of the invention, or PSCA. --

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 48

Please replace the paragraph at page 20, lines 28-31 and continuing through page 21, lines 1-6 with the following rewritten paragraph:

-- The term "PSCA" includes all naturally occurring allelic variants, isoforms, and precursors of human PSCA (SEQ ID NO:2) as provided in FIGS. 1B and 3 and murine PSCA (SEQ ID NO:4) as provided in FIG. 3. In general, for example, naturally occurring allelic variants of human PSCA will share significant homology (e.g., 70 - 90%) to the PSCA amino acid sequence provided in FIGS. 1B and 3. Allelic variants, though possessing a slightly different amino acid sequence, may be expressed on the surface of prostate cells as a GPI linked protein or may be secreted or shed. Typically, allelic variants of the PSCA protein will contain conservative amino acid substitutions from the PSCA sequence herein described or will contain a substitution of an amino acid from a corresponding position in a PSCA homologue such as, for example, the murine PSCA homologue described herein. --

Please replace the paragraph at page 21, lines 8-11 with the following rewritten paragraph:

-- One class of PSCA allelic variants will be proteins that share a high degree of homology with at least a small region of the PSCA amino acid sequences presented in FIGS. 1B (SEQ ID NO:2) and 3 (SEQ ID NO: 2 or 4), but will further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. Such alleles are termed mutant alleles of PSCA and represent proteins that typically do not perform the same biological functions.

--

Please replace the paragraph at page 21, lines 29-31 and continuing through page 22, lines 1-5 with the following rewritten paragraph:

-- The amino acid sequence of human PSCA protein (SEQ ID NO:2) is provided in FIGS. 1B and 3. Human PSCA is comprised of a single subunit of 123 amino acids and contains



Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 49

an amino-terminal signal sequence, a carboxy-terminal GPI-anchoring sequence, and multiple N-glycosylation sites. PSCA shows 30% homology to stem cell antigen-2 (SCA-2), a member of the Thy-1/Ly-6 gene family, a group of cell surface proteins which mark the earliest phases of hematopoietic development. The amino acid sequence of a murine PSCA homologue (SEQ ID NO:4) is shown in FIG. 3. Murine PSCA is a single subunit protein of 123 amino acids having approximately 70% homology to human PSCA and similar structural organization. --

Please replace the paragraph at page 22, lines 7-18 with the following rewritten paragraph:

-- PSCA proteins may be embodied in many forms, preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the PSCA protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated PSCA protein. A purified PSCA protein molecule will be substantially free of other proteins or molecules that impair the binding of PSCA to antibody or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of the PSCA protein include a purified PSCA protein and a functional, soluble PSCA protein. One example of a functional soluble PSCA protein has the amino acid sequence shown in FIG. 1B (SEQ ID NO:2) or a fragment thereof. In one form, such functional, soluble PSCA proteins or fragments thereof retain the ability to bind antibody or other ligand. --

Please replace the paragraph at page 22, lines 20-24 with the following rewritten paragraph:

-- The invention also provides peptides comprising biologically active fragments of the human (SEQ ID NO:2) and murine (SEQ ID NO:4) PSCA amino acid sequences shown in FIGS. 1B and 3. For example, the invention provides a peptide fragment having the amino acid sequence TARIRAVGLLTVISK (SEQ ID NO:16), a peptide fragment having

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 50

the amino acid sequence VDDSQDYVVGKK (SEQ ID NO:17), and  
SLNCVDDSQDYVVGK (SEQ ID NO:18). --

Please replace the paragraph at page 27, lines 20-31 and continuing at page 28, lines 1-3  
with the following rewritten paragraph:

-- Various methods for the preparation of antibodies are well known in the art. For example, antibodies may be prepared by immunizing a suitable mammalian host using a PSCA protein, peptide, or fragment, in isolated or immunoconjugated form (Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)). In addition, fusion proteins of PSCA may also be used, such as a PSCA GST-fusion protein. Cells expressing or overexpressing PSCA may also be used for immunizations. Similarly, any cell engineered to express PSCA may be used. This strategy may result in the production of monoclonal antibodies with enhanced capacities for recognizing endogenous PSCA. For example, using standard technologies described in Example 5 and standard hybridoma protocols (Harlow and Lane, 1988, Antibodies: A Laboratory Manual. (Cold Spring Harbor Press)), hybridomas producing monoclonal antibodies designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. HB-12616), 3E6 (ATCC No. HB-12618), and 3G3 (ATCC No. HB-12615), 4A10 (ATCC No. HB-12617) were generated. These antibody were deposited on December 11, 1998 with the American Type Culture Collection (ATCC), [ 12301 Parklawn Drive, Rockville, MD 20852 ] 10801 University Boulevard, Manassas, VA 20110-2209. --

Please replace the paragraph at page 36, lines 17-24 with the following rewritten paragraph:

-- The nucleotide sequence of a cDNA (SEQ ID NO:1) encoding one allelic form of human PSCA is provided in FIG. 1A. The nucleotide sequence of a cDNA (SEQ ID NO:3) encoding a murine PSCA homologue ("murine PSCA") is provided in FIG. 2. Genomic clones of human and murine PSCA have also been isolated, as described in Example 4. Both the human and murine genomic clones contain three exons encoding the

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 51

translated and 3' untranslated regions of the PSCA gene. A fourth exon encoding a 5' untranslated region is presumed to exist based on PSCA's homology to other members of the Ly-6 and Thy-1 gene families (FIG. 8). --

Please replace the paragraph at page 43, lines 25-30 and continuing through page 44, lines 1-2 with the following rewritten paragraph:

-- First, a nucleic acid molecule is obtained that encodes a PSCA protein (SEQ ID NO: 2 or 4) or a fragment thereof, such as the nucleic acid molecule depicted in FIG. 1A. The PSCA-encoding nucleic acid molecule is then preferably placed in an operable linkage with suitable control sequences, as described above, to generate an expression unit containing the PSCA-encoding sequence. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the PSCA protein. Optionally the PSCA protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated. --

Please replace the paragraph at page 81, lines 22-31 and continuing at page 82, lines 1-6, with the following rewritten paragraph:

-- Sequence analysis revealed that clone #15 had no exact match in the databases, but shared 30% nucleotide homology with stem cell antigen 2, a member of the Thy-1/Ly-6 superfamily of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens. Clone #15 encodes a 123 amino acid protein (SEQ ID NO:2) which is 30% identical to SCA-2 (SEQ ID NO:5) (also called RIG-E) and contains a number of highly conserved cysteine residues characteristic of the Ly-6/Thy-1 gene family (FIG. 3). Consistent with its homology to a family of GPI-anchored proteins, clone #15 contains both an amino-terminal hydrophobic signal sequence and a carboxyl-terminal stretch of hydrophobic amino acids preceded by a group of small amino acids defining a cleavage/binding site for GPI linkage (Udenfriend and Kodukula, 1995, Ann. Rev. Biochem. 64: 563-591). It also contains four predicted N-glycosylation sites. Because of its strong homology to the

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 52

stem cell antigen-2, clone #15 was renamed prostate stem cell antigen (PSCA). 5' and 3' PCR RACE analysis was then performed using cDNA obtained from the LAPC-4 androgen independent xenograft and the full length cDNA nucleotide sequence (including the coding and untranslated regions) was obtained. The nucleotide sequence of the full length cDNA (SEQ ID NO:1) encoding human PSCA is shown in FIG. 1A and the translated amino acid sequence (SEQ ID NO:2) is shown in FIG. 1B and in FIG. 3. --

Please replace the paragraph at page 87, lines 9-16 with the following rewritten paragraph:

-- The human PSCA cDNA was used to search murine EST databases in order to identify homologues for potential transgenic and knockout experiments. One EST obtained from fetal mouse and another from neonatal kidney were 70% identical to the human cDNA at both the nucleotide and amino acid levels. The homology between the mouse clones and human PSCA included regions of divergence between human PSCA and its GPI-anchored homologues, indicating that these clones likely represented the mouse homologue of PSCA. Alignment of these ESTs and 5' extension using RACE-PCR provided the entire coding sequence (SEQ ID NO:4) (FIG. 2). --

Please replace the paragraph at page 89, lines 3-17 with the following rewritten paragraph:

-- Generation and Production of Monoclonal Antibodies. BALB/c mice were immunized three times with a purified PSCA-glutathione S-transferase (GST) fusion protein containing PSCA amino acids 22-99 (SEQ ID NO:2) (FIG. 1B). Briefly, the PSCA coding sequence corresponding to amino acids 18 through 98 of the human PSCA amino acid sequence was PCR-amplified using the primer pair:

5'- GGAGAATTCATGGCACTGCCCTGCTGTGCTAC  
3'-GGAGAATTCCTAATGGGCCCCGCTGGCGTT

Applicant: Robert B. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 53

The amplified PSCA sequence was cloned into pGEX-2T (Pharmacia), used to transform *E. coli*, and the fusion protein isolated. --

Please replace the paragraph at page 105, lines 23-28, with the following rewritten paragraph:

-- Directly labeled fluorescent DNA probes for PSCA and for the 8q24 (*c-myc*) region were chosen. The PSCA cDNA (SEQ ID NO:1) (Fig. 1A) was used to identify a 130 kb bacterial artificial chromosome (bac) clone (PSCA probe) that in turn was used in the FISH analysis in accordance with the manufacturer's protocol (Genome Systems Inc.) The bac clone so identified and used in the FISH analysis was BACH-265B12 (Genome Systems, Inc. control number 17424). --

Please replace the paragraph at page 113, lines 16-24 with the following rewritten paragraph:

-- The lower panel of Figure 47 shows an ethidium bromide-stained agarose gel of RT-PCR analysis of murine PSCA transcript expression patterns in various mouse tissues. The RT-PCR was prepared using Ultraspec.RNA (Biotex), and cDNA cycle kit (Invitrogen). Primers corresponding to a region within exon 1 and exon 3 of PSCA were used to amplify a 320 bp fragment. The exon 1 primer sequence is as follows:

5' primer: 5'-TTCTCCTGCTGGCCACCTAC-3' (SEQ ID NO:8). The exon 3 primer sequence is as follows:

3' primer: 5'-GCAGCTCATCCCTTCACAAT-3' (SEQ ID NO:9). As a control, to demonstrate the integrity of the RNA samples isolated from the various mouse tissues, a 300 bp G3PD fragment was amplified. --

Please replace the paragraph at page 115, lines 15-20 with the following rewritten paragraph:

-- Murine monoclonal antibodies were raised against a GST-PSCA fusion protein comprising PSCA amino acid residues 18-98 of the PSCA amino acid sequence (SEQ ID

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 54

NO:2) (FIG. 1B) and expressed in E. coli, utilizing standard monoclonal antibody production methods. The following seven anti-PSCA monoclonal antibodies, produced by the corresponding hybridoma cell lines deposited with the American Type Culture Collection on December 11, 1998, were utilized in this study: --

Please replace the paragraph at page 128, lines 10-15 with the following rewritten paragraph:

-- First strand cDNA was synthesized from hybridoma RNA using a primer from the constant region of the heavy chain (CH3'). The variable region was amplified using CH3' and a primer designed to the leader sequence (HLEAD.1 and HLEAD.2). The resulting PCR product is sequenced and the complementarity determining regions (CDRs) are determined using the Kabat rules. The nucleotide (SEQ ID NOS:10, 12, and 14) and amino acid (SEQ ID NOS:11, 13, and 15) sequences are shown in FIGS. 58, 59 and 60, respectively. An amino acid alignment of the CDRs of these three Mabs is shown in FIG. 61. --

**In the claims:**

Please cancel claims 1 and 54-55 without prejudice to pursue the subject matter of these claims in a related application.

Please amend claim 53 as follows.

- 53. (amended) A Prostate Stem Cell Antigen (PSCA) protein fragment which induces an immune response in a subject, wherein the fragment comprises a portion of the PSCA protein, and the PSCA protein fragment is selected from the group consisting of:
- a. amino acid residues 2 through 50 as described in SEQ ID NO:2;
  - b. amino acid residues 85 through 123 as described in SEQ ID NO:2;

Applicant: Robert E. Reiter, et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 55

- c. amino acid residues 46 through 109 as described in SEQ ID NO:2;
- d. amino acid residues 18 through 98 as described in SEQ ID NO:2;
- e. amino acid residues 22 through 99 as described in SEQ ID NO:2;
- f. amino acid residues 21 through 50 as described in SEQ ID NO:2;
- g. amino acid residues 46 through 85 as described in SEQ ID NO:2;
- h. amino acid residues 50 through 64 as described in SEQ ID NO:2;
- i. amino acid residues 67 through 81 as described in SEQ ID NO:2;
- j. amino acid residues 21 through 99 as described in SEQ ID NO:2;
- k. amino acid residues 71 through 82 as described in SEQ ID NO:2;
- l. amino acid residues 85 through 99 as described in SEQ ID NO:2;
- m. amino acid residues 18 through 50 as described in SEQ ID NO:2;
- n. amino acid residues 46 through 98 as described in SEQ ID NO:2; or
- o. amino acid residues 85 through 98 as described in SEQ ID NO:2.